Free Research Report Download:
The Cancer Market Outlook To 2014
Free Pharmaceutical Market Research Reports
Biotechnology
Corporate & Fiscal
Drug Delivery
Health Products
Hospital Markets
Indication Areas
Medical Devices
Prescription Medicines
R&D
Custom Research
Pharmaceutical Events & Conferences
Contact
Terms & Conditions
Privacy
Stem Cell Technologies: World Market Outlook 2012-2022
Management Report
Published: May 2012
Pages: 202
Tables: For full details, please email deborahf@cmsinfo.com
From: GBP 1699.00 Buy Now!
Research from: pharmaceuticalmarketresearch
Sector: Biotechnology
What does the future hold for stem cells in medicine? Visiongain's report shows you potential revenues to 2022, assessing data, trends, opportunities and prospects there.
That new study lets you assess projected sales at world market and submarket level. You see discussions of work on stem cells in leading countries too - outlooks, challenges, patenting and regulations.
You see forecasting of world-level submarkets to 2022, finding potential revenues:
• Stem cell therapies
• Stem cell banks (e.g., cord blood banking)
• Ancillaries - adjunct technologies.
The technology is changing medicine through new therapies, methods and applications in drug development. Its scope is vast and promising, despite challenges.
With our study you also assess the R&D pipeline, seeing trends and outlooks. You find discussions of treatments in development, by therapeutic area and organisation:
• Autoimmune diseases - modifying the immune system
• Diabetes - restoring pancreatic function
• Oncology and cancer treatment
• Cardiovascular diseases - healing the heart and vascular system
• Neurological and cerebrovascular disorders - regenerating CNS tissue
• Ophthalmic disorders - potential for overcoming sight loss
• Bioartificial livers and hepatic regeneration with stem and progenitor cells
• Dermatology - developments in cellular skin repair
• Adipose-derived stem cells for autologous treatments
• Regenerative dentistry - potential for biotechnological tooth replacement.
You find prospects for embryonic, adult and induced pluripotent stem cells from 2012.
Market value for 2014 and prospects for the future
What will happen next? The biotechnology industry will develop many products using stem cells and increase revenues there from 2012 to 2022. The R&D pipeline is extensive. Overall world revenue will reach $7.3bn in 2014, our report forecasts.
Expansion of the market will result from new stem cell treatments and increased uptake of those technologies in drug development assays.
A diverse pipeline of therapies offers hope for treating many diseases. There are potential cures for diabetes, HIV and dry age-related macular degeneration (AMD).
Stem cell-based innovations tackle cardiovascular disorders, autoimmune diseases, metabolic disorders and many other conditions. Some of the breakthroughs will be a commercial reality by 2022, our investigation predicts.
What are companies doing? Our work profiles 187 organisations and investigates prospects of the industry and market. Examples include these developers and producers:
• Advanced Cell Technology
• Athersys
• Baxter Healthcare
• Bioheart
• Cytori Therapeutics
• Gamida Cell
• Mesoblast
• NeoStem
• Osiris Therapeutics
• TiGenix.
The scope of the field is widening, with many organisations entering and collaborating. You see how.
Haematopoietic stem cell transplantation is an established treatment. Revenues from transplants of bone marrow, peripheral blood and umbilical cord blood form much of the market in 2012. Those activities form a beginning, with many advances possible by 2020.
There are many commercial opportunities in stem cells, with high revenues possible from 2012 to 2022. New products will change medicine. Our report shows you and explains.
Forecasts, market shares, developmental trends, commercial news and discussions
In visiongain's report you find revenue forecasting, growth rates and market shares. Also, you see qualitative analyses (SWOT and STEP), company profiles and discussions of R&D activities. You receive 40 tables, 20 charts and six research interviews.
Eight ways Stem Cell Technologies: World Market Outlook 2012-2022 helps you
In particular, our study gives you the following knowledge on the topic:
• Find potential revenues to 2022 for the overall world market and submarkets
• Assess 187 prominent organisations, discovering activities and outlooks
• See discussions of stem cell work in the US, the UK, other prominent European countries, Israel, Japan, India, China and South Korea
• Review R&D pipelines, seeing trends and progress by therapeutic area
• Investigate competition and opportunities influencing sales
• Find out what will stimulate and restrain the industry and market
• Analyse prospects for established companies and those seeking to enter the sector
• View opinions from our survey, seeing interviews with authorities.
There, you discover quantitative and qualitative analyses with independent predictions. You receive information that only our report contains, staying informed on business intelligence.
Without our report you could miss out on information that your competitors use.
Gain research and analysis now for stem cells in healthcare
Our study is for everybody needing industry and market analyses for stem cells in medicine. You find data, predictions and answers there. Please order that report now.
Companies Listed
12th Guangzhou Municipal Hospital
3DM
Aastrom Biosciences
Abbott
Adistem
Advanced Cell Technology
Ageless Regenerative Institute
AiCuris
Aldagen
Alder Biopharmaceuticals
Alizyme
AllCells
Alliancells Bioscience Corporation
Alliqua
AlloCure
American Association of Blood Banks
Amgen
Amorcyte
AM-Pharma
Amstem Corporation
Angel Biotechnology
Angioblast
Angiotech
Anterogen
Antria
Apatech
Apceth
Applied Tissue Technologies
ArBlast
Arrow Therapeutics
Astellas Pharma
AstraZeneca
Aurigen Ventures
Aristotle University of Thessaloniki
Axcan Pharma
Arteriocyte
Athersys
Axiogenesis
Banc de Sang i Teixits
Barts & The London NHS Trust
Baxter Healthcare
Bayer
Beike Biotechnology
Beth Israel Deaconess Medical Center
BioE
Biogenea-Cellgenea
Biogen Idec
Bioheart
Biokine Therapeutics
BioLife Solutions
Biologic Therapies
Bio-Matrix Scientific Group
BioMet Orthopedics
BioMimetic Therapeutics
Biothera
Biotime
BrainStorm Cell Therapeutics
Bresagen
Cairo University
California Institute for Regenerative Medicine (CIRM)
Canadian Blood Services
Capricor
Capsant Neurotechnologies
Cardio3 Bioscience
Cardiogenesis Corporation
Celator Pharmaceuticals
Celgene Corporation
Cellartis
CellCentric
CellCyte Genetics
Celldex Therapeutics
Cell Dynamics
Cellectis
Cellerant Therapeutics
Cellerix
Cell Genesys
Cellgenia
CellGenix
Cell Medica
Cellonis Biotechnology
CellSeed
Cell Therapeutics
CellTran
Cellular Dynamics International
Center for International Blood and Marrow Transplant Research
Cephalon
Ceregene
Cha General Hospital, Seoul
Chimerix
Children's Hospital Los Angeles
Children's Memorial Hospital
Children's Oncology Group
China Cord Blood Corporation
Chinese Academy of Medical Sciences
Clal Biotechnology Institute
Cognate BioServices
Commissie Voor Klinisch Toegepast Onderzoek
CorCell
Cord Blood America
Corestem
Covance
Cryo-Cell International
CryoCord
Cryo-Save
CuraGen Corporation
CyDex Pharmaceuticals
CyThera
Cytheris
Cytomatrix
Cytori Therapeutics
CXR Biosciences
Dana-Farber Cancer Institute
Denali Ventures
Dendreon Corporation
Depuy
Eastern Cooperative Oncology Group
Eisai
Elbit Imaging
Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA
Eli Lilly and Company
Emory University
Enzon Pharmaceuticals
EpiStem
ES Cell International
European Group for Blood and Marrow Transplantation
European Medicines Agency (EMEA/EMA)
European Organization for Research and Treatment of Cancer - EORTC
Fate Therapeutics
Food and Drug Administration (US FDA)
FCB-Pharmicell
Fibrocell Science
First Affiliated Hospital of Zhejiang University
FortiCell Bioscience
Fred Hutchinson Cancer Research Center
Fresenius Biotech
Gamida Cell
Garnet BioTherapeutics
General BioTechnology
General Hospital of Chinese Armed Police Forces
General Hospital of Guangzhou Military Command of PLA
Genzyme
German Low Grade Lymphoma Study Group
Geron Bio-Med
Geron Corporation
Gilead Sciences
GlaxoSmithKline
Global Stem
GMP Unlimited
Hadassah Medical University
Hannover Clinical Trial Center
Harvard Stem Cell Institute (HSCI)
Harvest Technologies
Health20 (Zero G Cosmeceuticals)
Heinrich Heine University, Dusseldorf
HepaLife Technologies
Histogen
HomeoTherapy
Human Fertilisation and Embryology Authority (HFEA)
ImmunoCellular Therapeutics
Immunovative Therapies
Incyte
IntelliCell Biosciences
International Stem Cell Corporation
International Stemcell Services
InSCeption Biosciences
Instituto de Cardiologia do Rio Grande do Sul
Intercytex
Intermountain Health Care
iPierian
iPS Academia Japan
Isolagen
Israel Healthcare Venture
Israel Stem Cell Society
Ixion Biotechnology
Johann Wolfgang Goethe University Hospital
Johnson & Johnson
Kiadis Pharma
Kilburn & Strode LLP
King's College London
Korea Food and Drug Administration
Korea Stem Cell Bank
Leeds Cancer Centre at St. James's University Hospital
Licensing Solutions
LifebankUSA
Lifebank Cryogenics
Life Cell
LifeStem International
Liu Hua Qiao Hospital
Lonza
MacroPore Biosurgery
Magnafix
MaRS Innovation
Masonic Cancer Center, University of Minnesota
Massachusetts General Hospital
Maxcyte
Mayo Clinic
M.D. Anderson Cancer Center
MD Biosciences
Medac
MedCell Bioscience
Medipost
MedImmune
Medistem
Medizinische Klinik Mannheim
Medtronic
Merck & Co.
Merck Millipore
Meshalkin Research Institute of Pathology of Circulation
Mesoblast
MG Biotherapeutics
Miltenyi Biotec
Ministry of Health, Labour and Welfare (MHLW, Japan)
MK Alliance
Molecular Insight Pharmaceuticals
MolMed
Monash University
Monet Medical
Moorfields Eye Hospital
Mount Sinai Hospital
MultiCell Technologies
Nagoya University
National Cancer Institute
National Heart Institute, Mexico
National Heart, Lung and Blood Institute (NHLB)
National Institute of Allergy and Infectious Diseases (NIAID)
Nippon Zoki Pharmaceutical
National Marrow Donor Program, US
Neostem
Neuralstem
NeuroGeneration
Northern Therapeutics
North West Development Agency
Novartis
NovaThera - part of MedCell Bioscience
Novocell
Noxxon Pharma
NsGene
NuVasive
Odontis
Oligene
Opexa Therapeutics
OrbusNeich
Organogenesis
Orthofix
Osiris Therapeutics
Osteotech
Otsuka Pharmaceutical Development & Commercialization
Ottawa Hospital Research Institute
Parkinson's UK
PDL BioPharma
Pfizer
Pharmastem Therapeutics
Pierre Fabre Medicament
Plasticell
Pluristem Therapeutics
Polyphor
Poniard Pharmaceuticals
Postgraduate Institute of Medical Education and Research
Progencell
Progenitor Cell Therapies
Proneuron Biotechnologies
Quintiles
Rafa Laboratories
Rambam Health Care Campus
Regenavita
Regenerative Medicine Institute of Tijuana
Regenerative Sciences
RegeneRx Biopharmaceuticals
Regenetech
RegenTec
Regimmune
ReInnervate
Reliance Life Sciences
ReNeuron
Renovo
RenovoCyte
Renovo Neural
Reproductive Genetics Institute
RhinoCyte
Ribozyome
RNL Bio Company
Roche
Roslin Cellab
RTI Biologics
Samsung Medical Center
SanBio
Saneron CCEL Therapeutics
Scorpion Medical
Scottish Cancer Therapy Network
S-Evans Biosciences
Shanghai Jiao Tong University School of Medicine
Shenzhen Beike Bio-Technology
Shenzhen Zhongxing Yangfan Biotech
Skye Orthobiologics
Southwest Oncology Group
Spectrum Pharmaceuticals
Spinesmith Partners
State Food and Drug Administration (China)
Stem Cell Authority
StemCells
Stem Cell Innovations
Stem Cell Research Center of Peking University
Stem Cell Sciences
StemCell Services
Stem Cell Therapeutics
StemCell Technologies
StemCore
StemCore Laboratories
StemCyte
Stemedica Cell Technologies
Stemgent
Stemina Biomarker Discovery
Stempath
Stempeutics Research
Stemride International
St Jude Children's Research Hospital
St Mark's Hospital Foundation
St Theresa's Hospital, Bangalore
Swedish Orphan Biovitrum
Swiss Group for Clinical Cancer Research
Systemix
TaiGen Biotechnology
TAP Pharmaceutical Products
Tarix Pharmaceuticals
TCA Cellular Therapy
Technological Park of Ioannina
Technology Strategy Board of the UK Government
Tehran University of Medical Sciences
Tel Aviv University
Tengion
Terumo
Teva Pharmaceutical Industries
Theradigm
Therakos
TheraVitae
Theratechnologies
ThermoFisher Scientific
ThermoGenesis
TiGenix
Tissue Genesis
Tissue Regeneration Technologies
Titan Pharmaceuticals
TotipotentRX Cell Therapy
Toucan Capital
Transition Therapeutics
University College London
Tristem
Tarix Pharmaceuticals
Third Military Medical University
UK Stem Cell Bank
University College London
University Hospital, Caen
University Hospital Carl Gustav Carus
University Hospital, Limoges
University of Heidelberg
University of Kyoto
University of North Carolina
University of Queensland
University of Wisconsin
Vesta Therapeutics
VetCell
ViaCell
ViaCord
ViaCyte
Vical
Vion Pharmaceuticals
ViraCor Laboratories
ViroMed
ViroPharma
Vistagen Therapeutics
Vitro Biopharma
Vitro Diagnostics
Weizmann Institute of Science
WiCell
Xiamen Amoytop Biotech
Xcyte Therapies
XOMA
Yonsei University
Zhejiang Armed Police Hospital
Zhejian First People's Hospital